IART - Integra LifeSciences Holdings Corporation
| Previous Close | 57.33 |
| Open | 57.06 |
| Bid | 55.13 x 1100 |
| Ask | 60.00 x 800 |
| Day's Range | 55.24 - 57.15 |
| 52 Week Range | 42.14 - 67.50 |
| Volume | 216,445 |
| Avg. Volume | 469,952 |
| Market Cap | 4.712B |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | 76.79 |
| EPS (TTM) | 0.72 |
| Earnings Date | Apr 23, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.79 |
- Zacks•yesterday
Why Is Integra (IART) Down 0.5% Since Last Earnings Report?
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Markit•5 days ago
See what the IHS Markit Score report has to say about Integra LifeSciences Holdings Corp.
Integra LifeSciences Holdings Corp NASDAQ/NGS:IARTView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for IART with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold IART had net inflows of $4.67 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•9 days ago
Integra's Duragen Secures Japanese Nod to Drive Global Growth
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
- Simply Wall St.•9 days ago
Have Insiders Been Selling Integra LifeSciences Holdings Corporation (NASDAQ:IART) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
- GlobeNewswire•10 days ago
Integra LifeSciences Announces the Approval of DuraGen® in Japan
PLAINSBORO, N.J. and TOKYO, March 14, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, announces the recent approval of.
- Reuters•13 days ago
Integra gets FDA warning letter for Boston plant
Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston. The warning letter was issued after an inspection held at the facility in October and November last year, and flags issues related to its quality systems, the company said https://www.sec.gov/Archives/edgar/data/917520/000091752019000015/a8-kfiledmarch112019.htm. Sales of products manufactured in the Boston facility made up less than 4 percent of the company's revenue in 2018, Integra said, adding that it does not expect to incur material incremental expense related resolving the issues.
- GlobeNewswire•17 days ago
Integra LifeSciences to participate in Healthcare Conference in March 2019
PLAINSBORO, N.J., March 07, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following.
- Zacks•24 days ago
Integra Rides on Channel Expansion Strategy, New Alliances
Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
- Zacks•26 days ago
Integra's (IART) Q4 Earnings and Revenues Beat Estimates
Strength in the U.S. Codman Specialty Surgical business drives Integra LifeSciences' (IART) top line in Q4.
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of IART earnings conference call or presentation 21-Feb-19 1:30pm GMT
Q4 2018 Integra Lifesciences Holdings Corp Earnings Call
- Simply Wall St.•28 days ago
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) A Financially Sound Company?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Mid-caps stocks, like Integra LifeSciences Holdings Corporation (NASDAQ:IART) with aRead More...
Motley Fool•last monthIntegra Lifesciences Holdings Corp (IART) Q4 2018 Earnings Conference Call Transcript
IART earnings call for the period ending December 31, 2018.
- Zacks•last month
Integra LifeSciences (IART) Q4 Earnings and Revenues Top Estimates
Integra (IART) delivered earnings and revenue surprises of 4.84% and 0.56%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga•last month
The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
- Associated Press•last month
Integra: 4Q Earnings Snapshot
On a per-share basis, the Plainsboro, New Jersey-based company said it had net income of 29 cents. Earnings, adjusted for non-recurring costs, were 65 cents per share. The results beat Wall Street expectations. ...
- GlobeNewswire•last month
Integra LifeSciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Guidance
Fourth Quarter 2018 reported revenue increased 4.0% to $383.3 million; organic revenue increased 4.4% Fourth.
- Zacks•last month
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•last month
Integra LifeSciences Launches the Integra® Panta® 2 TTC Arthrodesis Nail System
PLAINSBORO, N.J., Feb. 13, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of the.
- Simply Wall St.•2 months ago
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Investing Effectively In Its Business?
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. Today we are going to look at Integra Read More...
- GlobeNewswire•2 months ago
Integra LifeSciences to Host Fourth Quarter and Full-Year 2018 Earnings Results Conference Call on February 21, 2019
PLAINSBORO, N.J., Jan. 31, 2019 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and.
- Zacks•2 months ago
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
- GlobeNewswire•2 months ago
Recent Analysis Shows T-Mobile US, Thor Industries, Integra LifeSciences, Diplomat Pharmacy, Tile Shop Hldgs, and Compass Diversified Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Jan. 10, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Integra LifeSciences Launches Integra® Titan™ Reverse Shoulder System-S
PLAINSBORO, N.J., Jan. 10, 2019 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the full market release.
